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Abstract
Chronic kidney disease (CKD) patients are given calcium carbonate to bind dietary phosphorus 
and reduce phosphorus retention, and to prevent negative calcium balance. Data are limited on 
calcium and phosphorus balance in CKD to support this. The aim of this study was to determine 
calcium and phosphorus balance and calcium kinetics with and without calcium carbonate in CKD 
patients. Eight stage 3/4 CKD patients, eGFR 36 mL/min, participated in two 3-week balances in a 
randomized placebo-controlled cross-over study of calcium carbonate (1500 mg/d calcium). 
Calcium and phosphorus balance were determined on a controlled diet. Oral and 
intravenous 45calcium with blood sampling and urine and fecal collections were used for calcium 
kinetics. Fasting blood and urine were collected at baseline and end of each week of each balance 
period for biochemical analyses. Results showed that patients were in neutral calcium and 
phosphorus balance while on placebo. Calcium carbonate produced positive calcium balance, did 
not affect phosphorus balance, and produced only a modest reduction in urine phosphorus 
excretion compared with placebo. Calcium kinetics demonstrated positive net bone balance but 
less than overall calcium balance suggesting tissue deposition. Fasting biochemistries of calcium 
and phosphate homeostasis were unaffected by calcium carbonate. If they can be extrapolated to 
effects of chronic therapy, these data caution against the use of calcium carbonate as a phosphate 
binder.
INTRODUCTION
Patients with chronic kidney disease-mineral bone disorder (CKD-MBD) have altered 
mineral metabolism due to disruptions in homeostasis of serum phosphate, calcium, and the 
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mineral-regulating hormones, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D 
(1,25D), and fibroblast growth factor-23 (FGF-23) (1). Progressive hypocalcemia and 
hyperphosphatemia as kidney function decreased were the original biochemical hallmarks of 
mineral bone disorder (2). Calcium and phosphorus absorption studies dating back to the 
1970s–80s (3–7) showed that intestinal calcium and phosphorus absorption were low in 
CKD and reversible with calcitriol and vitamin D analogs (7). Hypocalcemia from calcium 
malabsorption and hyperphosphatemia from phosphorus retention, were considered to be 
responsible for the progression of secondary hyperparathyroidism, a common feature of 
CKD (8). More recently it has been established that the reduced 1,25D is more likely due to 
elevation of the phosphate regulating hormone, FGF-23, which suppresses kidney 1-alpha 
hydroxylation of 25-hydroxyvitamin D (25D) and that PTH, FGF-23 and 1,25D form a 
sophisticated hormonal axis that regulate mineral homeostasis and skeletal mineralization 
(9).
There has been increasing awareness that abnormalities in the mineral regulating hormones 
occur early in kidney failure (CKD stage 2) before serum calcium and phosphorus move 
from their fasting reference ranges (10, 11). Increase in serum phosphate and phosphorus 
retention in CKD-MBD are considered to be the main culprits in exacerbating vascular and 
other soft tissue complications of CKD, and even within the normal reference range, serum 
phosphate is independently associated with increased mortality in pre-dialysis CKD patients 
(12). To prevent phosphate retention and hyperphosphatemia, use of phosphate binders in 
the management of end stage renal disease began in the mid-1970’s (13). Calcium carbonate 
as a phosphate binder was introduced in the mid-1980’s as an alternative to aluminum-based 
phosphate binders which carried the risk of aluminum toxicity (14). Calcium carbonate is a 
popular phosphate binder because of both its availability over the counter and its low cost 
relative to other phosphate binders. Not only does it bind dietary phosphate when given with 
meals but some believe it has the added advantage of preventing or reversing negative 
skeletal calcium balance, thought to contribute to the increased fracture risk in CKD (15, 
16). However, there is increasing concern over the risk of vascular calcification and 
cardiovascular events with use of calcium-based phosphate binders (17). There are only 
limited and inconsistent data regarding the safety of calcium-based versus non-calcium 
based binders (18). Until recently (19) no data on calcium balance in either early or late 
stage CKD patients were available and there are no studies utilizing calcium kinetics. One 
study (19) showed that stage 3 and 4 CKD patients were in neutral calcium balance while 
consuming an 800 mg/d calcium diet, and in positive calcium balance while consuming a 
diet of 2000 mg/d calcium. No equivalent data are available on phosphorus balance in CKD 
patients. The purpose of this study was to determine whether calcium carbonate, used as a 
phosphate binder, altered calcium and phosphorus balance and calcium kinetics in patients 
with stage 3/4 CKD while on a controlled diet. Further, the effects of calcium carbonate on 
fasting serum mineral and mineral-regulating hormone biochemistry were also determined.
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RESULTS
Patients
Seventeen volunteers were screened for the study. Five did not qualify based on the 
inclusion/exclusion criteria. Four enrolled patients were withdrawn from the study in the 
first week of study used both to assess dietary compliance and to equilibrate patients to the 
calcium and phosphorus content of the diet: three patients due to difficulties complying with 
the controlled diet and one patient due to starting kayexalate for high serum potassium. One 
patient who completed the study inadvertently remained on paricalcitol (2 mcg/d) during the 
study; despite this, this patient had the lowest calcium absorption out of all the study 
participants (6–7% on both placebo and calcium carbonate). Therefore, the data from this 
patient was retained in the analysis. Eight patients completed the entire study and were 
included in the analysis and results.
Patients participated in a randomized cross-over study of calcium carbonate (daily elemental 
calcium 2457 mg) versus placebo (daily elemental calcium 957 mg) (Figure 1). All eight 
patients were overweight based on body mass index and had hypertension, and six patients 
had type 2 diabetes mellitus. At baseline, serum calcium and serum phosphate were within 
normal ranges (8.8 to 10.2 mg/dL and 2.3 to 4.5 mg/dL for calcium and phosphate, 
respectively) (20) for all but one patient with serum calcium of 10.3 mg/dL and one patient 
with serum phosphate of 4.9 mg/dL. Six patients had serum PTH above the upper normal 
limit of the assay (54 pg/mL) and five patients had serum intact FGF-23 above the upper 
normal limit of the assay (54.3 pg/mL). Bone mineral density z-scores for total body, lumbar 
spine (L1–L4), and femoral neck were normal for age, race, and sex (Table 1). Usual dietary 
intake of calcium by 1-day dietary recall was 533 mg/d (range: 141 to 1211 mg/d) and 
phosphorus was 981mg/d (range: 351 to 1778 mg/d).
Steady-State and Compliance
As assessed by analysis of food leftovers, patients consumed > 90% of the prescribed dietary 
calcium and phosphorus. Calcium and phosphorus balance calculations were adjusted for 
calcium and phosphorus in leftover foods. Fecal calcium-to-polyethylene glycol (PEG) 
ratios showed that patients were in steady-state by the end of the 1-week equilibration 
period. Creatinine-corrected urine calcium and phosphate values differed minimally from 
uncorrected values (by 0.0 to 6.6 mg/d and 0.0 to 27 mg/d, respectively). Compliance for 
calcium carbonate and placebo was 100% for all participants as assessed by pill count.
Calcium Balance
On placebo (daily elemental calcium content 957 mg), calcium balance was neutral (not 
significantly different from zero). With calcium carbonate (daily elemental calcium content 
2457 mg), calcium balance was positive and significantly higher than placebo (508 vs. 61 
mg/d, respectively, p=0.002) (Figure 2). Fecal calcium was greater with calcium carbonate 
(1902 vs. 843 mg/d, p<0.0001). Urine calcium was not different between calcium carbonate 
and placebo (42 vs. 41 mg/d, p=0.95) (Figure 2). Net intestinal calcium absorption (Ca 
Intake – Fecal Ca) was higher with calcium carbonate (550 vs. 102 mg/d, p=0.002).
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Phosphorus Balance
Phosphorus balance was not significantly different from zero on placebo and did not differ 
between calcium carbonate and placebo (153 vs. 95 mg/d, p=0.2) (Figure 3). There were no 
differences between calcium carbonate and placebo for fecal phosphorus (822 vs. 722 mg/d, 
p=0.11), net intestinal phosphorus absorption (733 vs. 822 mg/d, p=0.13), or percent 
phosphorus absorption (47 vs. 53%, p=0.11). Urine phosphate excretion was significantly 
lower with calcium carbonate compared with placebo (580 vs. 728 mg/d, p=0.03) (Figure 3). 
The decrease in urine phosphate was 1 mg per 10 mg elemental calcium from calcium 
carbonate.
Calcium Kinetics
A schematic representation of calcium kinetics model is illustrated in Figure 4. Calcium 
carbonate resulted in greater rates of calcium absorption (Va, 416 vs. 211 mg/d, p=0.01 and 
bone balance (VBal, 259 vs. 62 mg/d, p=0.02). As percent of intake, calcium absorption was 
17 vs. 22%, p=0.35. Despite a significant difference in bone balance, the differences in rates 
of calcium deposition in bone (Vo+) and bone resorption (Vo−) were not significantly 
different between calcium carbonate and placebo (438 vs. 371 mg/d, p=0.17, and 179 vs. 
309 mg/d, p=0.12, respectively). Rate of endogenous calcium excretion was not different 
between calcium carbonate and placebo (Vf, 106 vs. 105 mg/d, p=0.95) (Figure 5).
Comparison of Calcium Balance and Kinetics in CKD Patients on Placebo with Healthy 
Adults
CKD patients not receiving calcium carbonate had lower urine calcium (46 vs. 121 mg/d, 
p=0.01) and fecal calcium (842 vs. 1092 mg/d, p=0.03) compared with healthy adult women 
[historical data (21)]. Calcium balance was higher in CKD patients compared with healthy 
adults (60 vs. −159 mg/d, p=0.03) (Supplemental Figure 1). Calcium kinetics data 
demonstrated that fractional calcium absorption tended to be lower in CKD patients 
compared with healthy adults (20 vs. 26%, p=0.09), but this difference was not statistically 
significant. Total calcium absorption (Va), endogenous calcium secretion (Vf), bone 
formation rate (Vo+), and bone resorption rate (Vo−) were not different between CKD 
patients and healthy adults. Bone balance (VBal) was greater in CKD patients compared with 
healthy adults (57 vs. −108 mg/d, p=0.03) (Figure 6). No equivalent data on phosphorus 
balance are available on these controls.
Fasting Biochemistries
Fasting serum calcium and phosphate were within normal reference ranges and did not differ 
between calcium carbonate and placebo (Table 2). Fasting serum 25D was within normal 
range but was slightly lower with calcium carbonate (25.1 vs. 26.7 ng/mL, p=0.03). Fasting 
serum PTH and FGF-23 were higher than the normal ranges for the assays, while fasting 
serum 1,25D was within but in the lower end of the normal range for the assay. Serum 
osteocalcin (OC) was higher than the normal range, and serum bone alkaline phosphatase 
(BAP) and urine N-telopeptides of type I collage (NTX) were normal. None of these 
measures differed between calcium carbonate and placebo.
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Kidney Function and Mineral Handling
Kidney function measurements (eGFR, serum creatinine, and creatinine clearance) were not 
different between calcium carbonate and placebo (data not shown). Urine Ca/Cr, tubular 
maximal reabsorption of calcium (TmCa), and fractional calcium excretion (CCa/CCr) were 
not different between calcium carbonate and placebo (Table 2). Urine Pi/Cr and fractional 
phosphate excretion (CPi/CCr) tended to be lower and tubular maximal reabsorption of 
phosphate (TmP) tended to be higher with calcium carbonate compared with placebo, but 
these differences were not statistically significant.
DISCUSSION
This three-week placebo-controlled balance and kinetic study demonstrated that stage 3/4 
CKD patients were in neutral calcium balance while consuming a diet adequate (22) in 
calcium containing 957 mg per day. Increasing calcium intake with 500 mg calcium from 
calcium carbonate taken with three daily meals produced positive calcium balance. The 
ability of CKD patients to maintain neutral calcium balance on an adequate calcium diet was 
largely due to low urine calcium excretion, and to achieve positive calcium balance with 
calcium carbonate was largely due to increased calcium absorption and net retention, and 
failure to increase urine calcium excretion. The study demonstrated that phosphorus balance 
was also neutral on an average (23) U.S. intake of phosphorus of 1564 mg per day. Further, 
phosphorus balance was unaffected by calcium carbonate even although there was a 
reduction in urine phosphate excretion of about 148 mg/d. Thus, the overall effect of a 500 
mg calcium supplement with three meals per day in CKD stage 3/4 patients was to produce 
a large positive calcium balance without affecting neutral phosphorus balance and only a 
modest effect on reducing urine phosphate. The decrease in urine phosphate was about 1mg 
for every 10mg elemental calcium supplement which is close to that found by others (24). 
The reduction in urine phosphate was likely due to a reduction in phosphate absorption 
although the increase in fecal phosphorus with the calcium supplement was not significant 
probably reflecting greater imprecision in the fecal phosphorus measurement.
Calcium kinetics demonstrated that calcium carbonate increased bone formation and 
decreased bone resorption and improved bone balance by about 200 mg/day. Calcium 
kinetic modeling is currently unable to estimate the rate of calcium deposition into 
extraskeletal tissues. However, overall calcium balance measured by chemical methods, 
after subtracting 79 mg calcium /day in sweat (25) showed an increase in calcium balance of 
over 300 mg/day, suggesting that an appreciable proportion of the retained calcium from 
calcium carbonate was deposited in extraskeletal tissue and/or in the skeleton independent of 
bone formation and resorption mechanisms.
It is generally assumed that CKD patients have phosphorus retention due to the need to 
excrete normal dietary phosphorus by increasing serum phosphate to accommodate for 
decreased GFR. However, this study demonstrated that despite phosphate retention in 
serum, CKD patients stage 3/4 remain in overall neutral phosphate balance. Phosphorus 
balance studies have not been performed previously in CKD patients partly because of 
concern over the accuracy of measuring fecal phosphorus (26, 27). Analysis of phosphorus-
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spiked fecal samples showed that the method used in this study (Supplemental methods) 
gives 92.2% (82.5–100.5%) mean recovery.
Small sample size may have limited our ability to detect significant differences of calcium 
and phosphorus balance from zero since the study was only powered to detect mean 
differences in balance between calcium carbonate and placebo. However, normal bone 
mineral density of the patients corroborates that they were not in long-term negative calcium 
balance on their habitual calcium intakes of 533 mg/d. Also the potential bias towards 
underestimating fecal phosphorus and thus overestimating phosphorus balance lends support 
to the conclusion that these patients are not retaining phosphorus while consuming a liberal 
amount of dietary phosphorus.
Fasting serum phosphate was unaffected by calcium carbonate, despite a decrease in urine 
phosphate. Additionally, the hormones regulating phosphorus homeostasis, PTH, 1,25D, and 
FGF-23, were not affected by calcium carbonate indicating that the decrease in phosphate 
excretion with calcium carbonate was insufficient to elicit changes in phosphorus 
homeostasis. Perhaps longer treatment periods are needed to observe changes in serum 
phosphate and its regulating hormones since studies with sevelamer showed a reduction in 
FGF-23 in dialysis patients (28) over four weeks and a reduction in FGF-23 and PTH in 
normophosphatemic CKD patients over six weeks (29).
To assess the abnormalities that occur in CKD patients, calcium balance and kinetics were 
compared with historical data (21) from healthy postmenopausal women on a similar 
calcium-controlled diet. CKD patients had lower urine calcium and lower fractional calcium 
absorption than postmenopausal women. Importantly, calcium balance was higher in CKD 
patients, providing further support that stage 3/4 CKD patients are not in negative calcium 
balance. The strength of these comparisons is that the historical data were generated by the 
same research group using the same methodologies in healthy postmenopausal women of 
similar age to the CKD patients.
Calcium balance studies combined with calcium kinetics in subjects in mineral equilibrium 
are the gold standard for measuring rates of calcium transport at gut, bone and kidney. Using 
the standard one week of dietary and environmental equilibration followed by two weeks of 
balance (32) our patients were well equilibrated as corroborated by constant outputs of fecal 
and urinary markers. As in most balance studies, the dietary calcium and phosphorus intake 
was fixed by protocol to be close to the average intake in the USA, and not on each patient’s 
usual intake. Balance utilizing a randomized cross-over intervention represents a strong 
study design to test the effects of a treatment on mineral balance. On the other hand, balance 
studies are very exacting both for patient and investigator and they inevitably suffer from 
small sample size. Further, in this study as is typical of stage 3/4 CKD, the patients were not 
a homogenous sample and included men and women, American blacks and whites and a 
high incidence of obesity and type 2 diabetes, all factors known to affect mineral 
metabolism and bone mass. Thus the results may not be directly generalizable to all stage 
3/4 CKD patients or to all dietary levels of calcium and phosphorus intake. Further, the 
results may not reflect the effects of chronic therapy on mineral balance.
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This study is the first balance study in CKD to include both calcium and phosphorus balance 
and calcium kinetics, and to evaluate the effects of calcium carbonate on these measures. 
These results challenge the rationale for using calcium-based phosphate binders in stage 3/4 
CKD patients to prevent negative calcium balance, reduce PTH, reduce serum phosphate, 
and prevent phosphorus retention because: 1) patients were not in negative calcium balance 
or positive phosphorus balance on placebo, and 2) calcium carbonate did not affect serum 
PTH, serum phosphate, or phosphorus balance. Although it is unknown whether the calcium 
retained from calcium carbonate is deposited into bone or soft tissue in these patients, it is 
unlikely that bone could serve as the sole reservoir considering the magnitude of the positive 
calcium balance and the patients’ age. Therefore, the positive calcium balance produced by 
calcium carbonate cautions against its use as a phosphate binder in stage 3/4 CKD patients.
METHODS
Patients and Study Design
Men and women ≥35 years old with GFR < 45 mL/min and serum PTH ≥ mid normal range 
mean were recruited (Table 1 and Supplemental Methods) and studied on the Indiana 
Clinical Research Center under an Institutionally Review Committee approved protocol 
using a randomized cross-over design (Figure 1).
Controlled Diet, Calcium Intervention, and Compliance
The controlled diet, given as a 4-day cycle menu (Supplemental Methods) , contained 957 ± 
23 mg/d calcium (22) and 1564 ± 52 mg/d phosphorus (23). Energy requirements (30) 
matched the patients’ needs; distilled water was provided as desired; and 400 IU/d of oral 
vitamin D3 (Finest Natural® softgels) was given for two weeks before and throughout the 
balance. Calcium carbonate (Calci-Mix®, Rugby Laboratories, Duluth, GA) was given as a 
capsule contained 500 mg elemental calcium three times a day with meals and placebo was 
given as identical capsules. During the equilibrium week1, study food was packed and 
labeled for each meal and patients kept diet and pill checklists and returned any unconsumed 
food and pills. During week 2 and 3, patients were inpatients and meals were served and 
pills administered and by research staff. Dietary compliance was assessed by meal checklists 
and leftover food was recorded, weighed, and saved for analysis. Pill compliance was 
assessed by pill count. Polyethylene glycol (PEG, 3 g/d), a non-absorbable marker, was 
given with meals to assess steady state and was measured in feces using a turbidimetric 
assay (31). Urine creatinine from 24 h collections was used to assess urine collection 
compliance.
Calcium and Phosphorus Balance
The balance technique is described in further detail in Supplemental Methods. Previous data 
in healthy adults (32) show six days are needed to achieve steady state on a new dietary 
calcium intake level. Therefore, the first week of the 3-week study period was as an 
outpatient and was used both as an equilibration period to the diet to achieve steady state 
and as an assessment for compliance with the diet. All urine and feces were collected during 
week 2 and 3. Urine was pooled into 24 h collections and calcium and phosphorus measured 
by inductively coupled plasma optical emission spectrometry (ICP-OES). Feces were pooled 
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and homogenized by day of collection and aliquots ashed at 600°C (for calcium) and 550°C 
(for phosphorus), and analyzed by ICP-OES. A modified version of the dry-combustion 
method described by Yokato et al. (27) was used for fecal phosphorus analysis 
(Supplemental Methods). Urine creatinine was measured by colorimetric assay using a 
COBAS MIRA clinical analyzer (Roche Diagnostic, Indianapolis, IN). Balance and net 
absorption were calculated as the average (mg/d) over week 2 and 3: mineral balance (mg/d) 
= dietary intake minus urine and fecal excretion; net absorption (mg/d) = dietary intake 
(mg/d) minus fecal excretion (mg/d). Absorption as percent of intake (%) was calculated as 
net absorption (mg/d)/dietary intake of mineral (mg/d)*100.
Calcium Kinetics
Calcium kinetics provides a direct measure of bone formation and resorption and balance, 
absorption and endogenous secretion and is described in further detail in the Supplemental 
Methods. On the first inpatient day, patients were orally administered 10μCi 45Ca as CaCl2 
in sterile saline mixed in 2% milk with breakfast that contained a third of the daily total 
calcium intake (approximately 300 mg (diet alone) on placebo and 800 mg (diet plus 
supplement) on calcium carbonate). Blood was collected prior to dosing, and at 1, 2, 3, 6, 
and 24 hours thereafter. On the second inpatient day 1 hour after breakfast, patients were 
intravenously administered 10μCi 45Ca as CaCl2 in sterile saline. Blood samples were 
collected prior to dosing and at 5, 10, 20, 40 minutes and 1.5, 2, 2.5, 3, 4, 5, 7, 10, 24, 36 
hours, and 2, 3, 5, 7, 9, 11, and 18 days thereafter. 45Ca activity of urine, serum, and feces 
was measured by beta liquid scintillation counting (LS6500, Beckman Coulter) and used in 
a multi-compartment model (33–35) (Figure 4).
Fasting Biochemical Measures and Derived Variables
Fasting serum and urine were collected at baseline and the end of week 1,2 and 3 and stored 
at −80°C until analyzed. Serum osteocalcin and bone alkaline phosphatase were measured 
by EIA (MicroVueTM, Quidel, San Diego, CA), PTH by IRMA (N-tact®, DiaSorin, 
Stillwater, MN, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by RIA (Diasorin, 
Stillwater, MN), and intact fibroblast growth factor-23 by ELISA (Kainos Laboratories, Inc., 
Tokyo, Japan,); urine cross-linked N-telopeptides of type 1 collagen (NTX) was measured 
by EIA (Osteomark®, Wampole Laboratories, Princeton, NJ). Serum and urine calcium, 
phosphate, and creatinine were measured by colorimetric assay using a COBAS MIRA 
clinical analyzer (Roche Diagnostic, Indianapolis, IN).
Estimate glomerular filtration rate was calculated by the MDRD Study equation (36, 37), 
creatinine clearance was calculated by V (mL/min)* urine Cr (mg/dL)/serum (mg/dL) from 
average 24 h urine volume and creatinine and serum creatinine during week 2 and 3.Tubular 
maximum reabsorption of phosphate (TmP), calcium (TmCa), fractional excretion of 
calcium (Cca/Ccr), and fractional excretion of phosphate (Cpi/Ccr ; FEphos)were calculated 
from fasting serum and 2 h urine (see Supplemental Methods).
Anthropometrics, Body Composition, Bone Densitometry, and Usual Dietary Intake
Height (cm) and weight (kg) were measured at week 2 and 3. Body mass index was 
calculated as kg/m2. Bone mineral density (BMD, mg/cm2, z-score) and body composition 
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were determined at baseline by dual-energy x-ray absorptiometry (Lunar Prodigy Advance, 
GE Healthcare). A 24-hour dietary recall was obtained using online software (ASA24TM 
beta version, National Cancer Institute) to assess usual dietary intake.
Calcium Balance and Kinetics Comparison of CKD Patients on Placebo with Healthy 
Adults
Calcium balance and kinetics were compared with historical data from 13 healthy 
postmenopausal women (mean age 57 ± 6 years) studied by our group (21) using exactly the 
same calcium balance and kinetic methodologies as used in the present study. Data from 
CKD patients during the placebo arm (calcium intake = 957 mg/d) were compared with data 
from the healthy postmenopausal women who were consuming a controlled diet of 1083 
mg/d calcium. Means, standard deviations, and sample sizes were used to calculate two-
tailed independent t-tests to determine differences between CKD patients and healthy 
postmenopausal women. These data are presented as means ± pooled SEM.
Statistical Analysis
One-sample t-tests were used to test if calcium and phosphorus balances on placebo and 
calcium carbonate were different from zero (38). These data are presented as mean ± 
standard error of the mean (SEM). The differences in outcome measures between calcium 
carbonate and placebo were analyzed using repeated measures ANOVA for cross-over 
designs (39, 40). These data are presented as least squares mean (lsmeans) ± pooled SEM. 
Statistical analysis was performed using SAS® 9.2 (SAS Institute, Cary, NC). The 
significance level was set at α = 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Randomized cross-over study design.
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Figure 2. 
Calcium balance in stage 3/4 CKD patients with and without calcium carbonate. Calcium 
balance was greater with calcium carbonate compared with placebo. Ca intake was 
experimentally controlled and statistical analysis does not apply. White bars = placebo; 
Black bars = calcium carbonate. Ca = calcium; NS = not significant (p > 0.05). Data are 
presented as least squares mean ± pooled SEM.
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Figure 3. 
Phosphorus balance in stage 3/4 CKD patients with and without calcium carbonate. 
Phosphorus balance was not different between calcium carbonate and placebo but urine 
phosphate was lower on calcium carbonate. P intake was experimentally controlled and 
statistical analysis does not apply. White bars = placebo; Black bars = calcium carbonate. P 
= phosphorus; NS = not significant (p > 0.05). Data are presented as least squares mean ± 
pooled SEM.
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Figure 4. 
Illustration of calcium kinetics (33). ECF = extracellular compartment. 45Ca = 45Calcium 
radiotracer; Va = rate of calcium absorption; Vf = rate of endogenous calcium excretion; VF 
= rate of fecal calcium excretion; Vu = rate of urine calcium excretion; Vo+ = rate of bone 
formation; Vo− = rate of bone resorption. Bone balance is Vo+ minus Vo−, and overall 
calcium retention is dietary calcium minus urine and fecal calcium.
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Figure 5. 
Calcium kinetics in stage 3/4 CKD patients with and without calcium carbonate. Calcium 
absorption (Va, mg/d) and bone balance (VBal=Vo+ minus Vo− ) were higher, and 
endogenous secretion (Vf) was unchanged with calcium carbonate compared with placebo. 
White bars = placebo; Black bars = calcium carbonate. Ca = calcium; NS = not significant 
(p > 0.05). Data are presented as least squares mean ± pooled SEM.
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Figure 6. 
Comparison of calcium kinetics on placebo of stage 3/4 CKD patients with healthy 
postmenopausal women. Stage 3/4 CKD patients (white bars, n = 8, current study, on 
controlled diet + placebo) had similar rate of calcium absorption (Va), endogenous calcium 
excretion (Vf), bone formation (Vo+), bone resorption (Vo−), and “bone” balance (VBal) 
compared with healthy postmenopausal women [grey bars, n = 13, historical data (21)]. Data 
are presented as mean ± pooled SEM.
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Table 1
Patient Demographics and Baseline Characteristicsa
Male/Female, n 2/6
Black/White, n 5/3
Diabetes present, n 6
Hypertension present, n 8
Age, years 58.5 ± 6.9 (47.2, 68.7)
BMI, kg/m2 38.7 ± 8.7 (27.9, 52.2)
eGFR, mL/min/1.73m2 36 ± 8.8 (26, 53)
serum Ca, mg/dL 9.6 ± 0.3 (9.3, 10.3)
serum Pi, mg/dL 3.8 ± 0.6 (3.2, 4.9)
serum PTH, pg/mL 84.5 ± 58.7 (36.6, 214.0)
serum Intact FGF-23, pg/mL 79.4 ± 39.7 (33.7, 149.6)
Total Body BMD, g/cm2 1.26 ± 0.10 (1.11, 1.38)
Z-score 0.4 ± 1.0 (−0.8, 1.9)
Lumbar Spine BMD, g/cm2 1.29 ± 0.21 (0.98, 1.51)
Z-score 0.5 ± 1.5 (−1.3, 2.6)
Femoral Neck BMD, g/cm2 0.98 ± 0.12 (0.80, 1.11)
Z-score −0.5 ± 0.5 (−1.3, 0.3)
aValues are means ± SD (min, max) unless otherwise noted. N = 8. BMD z-scores are matched for age, race, and sex.
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